NVision’s POLARIS Quantum Sensor Deployed at 20 Cancer Centers Worldwide This Year

A $55 million Series B financing round, with Abbott as the lead investor, is fueling NVision’s expansion beyond quantum sensing and into quantum computation, a move expected to reshape drug development timelines. The company is deploying its operational POLARIS systems, which enhance MRI signals using quantum technology to measure metabolism in hours instead of months, at approximately 20 cancer centers worldwide this year, including Memorial Sloan Kettering and the University of Cambridge. While developing POLARIS, NVision researchers discovered a new class of organic molecule-based qubits, forming the foundation for its Photonic Integrated Quantum Circuits. “I see a future where quantum computers generate many drug hypotheses for diseases that are difficult to treat today,” said Sella Brosh, CEO and Co-Founder of NVision.

POLARIS Quantum Sensing Enhances Real-Time Metabolic Measurement

Beyond securing funding, NVision is extending its focus from quantum sensing, demonstrated in its POLARIS platform, into quantum computation, aiming for an integrated approach to therapy design. POLARIS utilizes quantum technology to amplify the signal from sugar-based imaging agents during MRI scans, facilitating real-time metabolic measurements; this allows researchers to assess treatment efficacy within days, a significant improvement over conventional imaging methods that often require months to detect morphological changes. This faster speed is critical because diagnostic delays hinder rapid clinical translation of research findings. Approximately 20 cancer centers are receiving POLARIS systems.

POLARIS is designed for practical application within existing hospital environments, eliminating the need for specialized quantum expertise, demonstrating that quantum technologies can deliver tangible benefits quickly. “NVision is fundamentally changing how we find, diagnose, and treat cancer by making the biology of disease visible in ways that weren’t possible before,” said Peter Barrett, General Partner, Playground Global. The foundation for this expansion lies in an unexpected discovery during POLARIS development: a novel class of organic molecule-based qubits. These qubits are being integrated into Photonic Integrated Quantum Circuits (PIQC), leveraging established semiconductor manufacturing techniques for scalability. NVision aims to accelerate drug discovery through quantum computing, generating numerous drug candidates and validating them rapidly with POLARIS’s biological assessments. As we expand our ambition into quantum computing, building on our remarkable new class of organic molecule-based qubits, that future comes closer.

Organic Molecule Qubits Drive Photonic Integrated Quantum Circuits

The convergence of quantum computation and biophotonics is accelerating, with NVision using a novel approach centered on organic molecule-based qubits. This expansion represents a shift, moving NVision beyond quantum sensing and into designing new therapies. These newly discovered qubits are not based on superconducting loops or trapped ions, but rather on single photon emitting organic molecules formed as a thin layer directly onto photonic chips. This architecture, designed for scalability, leverages existing semiconductor manufacturing processes, offering a potential pathway to building practical quantum computers. The company’s strategy is to combine the computational power of these PIQCs with the validation capabilities of POLARIS, creating a loop for accelerated drug discovery.

Peter Karabatsos, Divisional Vice President of New Technology at Abbott, emphasized the company’s interest in NVision’s ability to translate complex quantum science into scalable, real-world systems, noting, “What stands out to us about NVision is their ability to turn complex quantum science into scalable systems for real-world use.” The investment reflects growing confidence in quantum technologies’ potential to revolutionize healthcare, offering earlier insights into disease biology and enabling new approaches to clinical decision-making.

$55 Million Series B Fuels Quantum Computing Expansion

NVision, a company pioneering quantum technologies for healthcare, has secured $55 million in Series B funding, with Abbott as the lead investor; this financial injection signals pharmaceutical industry endorsement of quantum computing’s potential within medical applications. Beyond bolstering the company’s financial standing, the funding will facilitate a substantial expansion of NVision’s capabilities, moving beyond its established quantum sensing platform, POLARIS, into quantum computation. The company’s POLARIS system is already undergoing installation at approximately 20 leading cancer centers across the U.S. Unlike many quantum projects, POLARIS doesn’t necessitate specialized quantum expertise, highlighting its immediate value in clinical settings; it enhances MRI signals using quantum principles to measure metabolism in real-time, drastically reducing diagnostic timelines from months to days. This capability is crucial for assessing treatment response based on biological changes, rather than relying on traditional morphological assessments. NVision’s ambition is to create a unified approach, leveraging quantum computing for drug design and POLARIS for rapid in vivo validation.